Detail akcie Regeneron Pharm online

Business Summary: Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Regeneron Pharmaceuticals Inc revenues increased 6% to $6.69B. Net income increased 21% to $2.15B. Revenues reflect Sanofi segment increase of 18% to $2.06B, Libtayo segment increase of 42% to $341.6M. Net income benefited from Changes in the fair value of our equity increase from $195.6M (expense) to $196.3M (income), Interest Income - Non-Bank increase of 60% to $340.9M (income).